Empiric treatment options in the management of complicated intra-abdominal infections

Cleveland Clinic Journal of Medicine

Volumn 74, Issue SUPPL.4, 2007, Pages 29-37

  Weigelt, John A ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; CARBAPENEM DERIVATIVE; DORIPENEM; DRUG DERIVATIVE; MINOCYCLINE; TIGECYCLINE;

ANTIBIOTIC RESISTANCE; COMMUNICABLE DISEASE; CROSS INFECTION; HOSPITALIZATION; HUMAN; INTERNAL MEDICINE; MICROBIOLOGY; PERITONEAL CAVITY; PERITONITIS; REVIEW; RISK FACTOR; SURGERY; SURGICAL INFECTION;

ANTI-BACTERIAL AGENTS; CARBAPENEMS; COMMUNITY-ACQUIRED INFECTIONS; CROSS INFECTION; DRUG RESISTANCE, BACTERIAL; HUMANS; INTERNAL MEDICINE; MINOCYCLINE; PERITONEAL CAVITY; PERITONITIS; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SURGERY; SURGICAL WOUND INFECTION;

EID: 35748981241     PISSN: 08911150     EISSN: None     Source Type: Journal    
DOI: 10.3949/ccjm.74.Suppl_4.S29     Document Type: Article

References (59)

1. Solomkin JS, Mazuski JE, Baron EJ, et al. Guidelines for the selection of anti-infective agents for complicated intra-abdominal infections. Clin Infect Dis 2003; 37:997-1005.
2. Lorber B, Swenson RM. The bacteriology of intraabdominal infections. Surg Clin North Am 1975; 55:1349-1354.
3. Solomkin JS, Hemsell DL, Sweet R, et al. Evaluation of new antiinfective drugs for the treatment of intra-abdominal infections. Clin Infect Dis 1992; 15:S33-S42.
4. Marshall JC. Intra-abdominal infections. Microbes Infect 2004; 6:1015-1025.
5. Nathens AB, Rotstein OD, Marshall JC. Tertiary peritonitis: clinical features of a complex nosocomial infection. World J Surg 1998; 22:158-163.
6. Cattan P, Yin DD, Sarfati E, Lyu R, De Zelicourt M, Fagnani F. Cost of care for inpatients with community-acquired intra-abdominal infections. Eur J Clin Microbiol Infect Dis 2002; 21:787-793.
7. Barie PS, Hydo LJ, Eachempati SR. Longitudinal outcomes of intra-abdominal infection complicated by critical illness. Surg Infect (Larchmt) 2004; 5:365-373.
8. Lally KP, Cox CS, Andrassy RJ. Appendix. In: Townsend CM Jr, Beauchamp RD, Evers BM, Mattox KL, eds. Sabiston Textbook of Surgery: The Biological Basis of Modern Surgical Practice. 17th ed. Philadelphia, PA: Elsevier Saunders; 2004:1381-1399.
9. Farthmann EH, Schoffel U. Epidemiology and pathophysiology of intraabdominal infections (IAI). Infection 1998; 26:329-334.
10. Mazuski JE, Sawyer RG, Nathens AB, et al. The Surgical Infection Society guidelines on antimicrobial therapy for intra-abdominal infections: evidence for the recommendations. Surg Infect (Larchmt) 2002; 3:175-233.
11. Christou NV, Barie PS, Dellinger EP, Waymack JP, Stone HH. Surgical Infection Society intra-abdominal infection study: prospective evaluation of management techniques and outcome. Arch Surg 1993; 128:193-198.
12. Dellinger EP, Wertz MJ, Meakins JL, et al. Surgical infection stratification system for intra-abdominal infection: multicenter trial. Arch Surg 1985; 120:21-29.
13. Ohmann C, Wittmann DH, Wacha H. Prospective evaluation of prognostic scoring systems in peritonitis. Peritonitis Study Group. Eur J Surg 1993; 159:267-274.
14. Wacha H, Hau T, Dittmer R, Ohmann C. Risk factors associated with intraabdominal infections: a prospective multicenter study. Peritonitis Study Group. Langenbecks Arch Surg 1999; 384:24-32.
15. Bohnen JM, Mustard RA, Schouten BD. Steroids, APACHE II score, and the outcome of abdominal infection. Arch Surg 1994; 129:33-37.
16. Pacelli F, Doglietto GB, Alfieri S, et al. Prognosis in intra-abdominal infections. Multivariate analysis on 604 patients. Arch Surg 1996; 131:641-645.
17. Hopkins JA, Lee JCH, Wilson SE. Susceptibility of intra-abdominal isolates at operation: a predictor of postoperative infection. Am Surg 1993; 59:791-796.
18. Christou NV, Turgeon P, Wassef R, et al. Management of intraabdominal infections. The case for intraoperative cultures and comprehensive broad-spectrum antibiotic coverage. Arch Surg 1996; 131:1193-1201.
19. Montravers P, Gauzit R, Muller C, et al. Emergence of antibioticresistant bacteria in cases of peritonitis after intra-abdominal surgery affects the efficacy of empirical antimicrobial therapy. Clin Infect Dis 1996; 23:486-494.
20. Finegold SM. Microflora of the gastrointestinal tract. In: Wilson SE, Finegold SM, Williams RA, eds. Intraabdominal Infection. New York, NY: McGraw-Hill; 1982:1-21.
21. Dougherty SH. Role of enterococcus in intraabdominal sepsis. Am J Surg 1984; 148:308-312.
22. Hopkins JA, Lee JCH, Wilson SE. Susceptibility of intra-abdominal isolates at operation: a predictor of postoperative infection. Am Surg 1993; 59:791-796.
23. Burnett RJ, Haverstock DC, Dellinger EP, et al. Definition of the role of enterococcus in intraabdominal infection: analysis of a prospective randomized trial. Surgery 1995; 118:716-723.
24. de Vera ME, Simmons RL. Antibiotic-resistant enterococci and the changing face of surgical infections. Arch Surg 1996; 131:338-342.
25. Smith TL, Pearson ML, Wilcox KR, et al. Emergence of vancomycin resistance in Staphylococcus aureus. N Engl J Med 1999; 340:493-501.
26. Levison ME, Bush LM. Peritonitis and other intra-abdominal infections. In: Mandell GL, Bennett JE, Dolin R, eds. Principles and Practice of Infectious Disease. 5th ed. New York, NY: Churchill Livingstone; 2000:821-856.
27. Berne TV, Yellin AW, Appleman MD, Heseltine PN. Antibiotic management of surgically treated gangrenous or perforated appendicitis: comparison of gentamicin and clindamycin versus cefamandole versus cefoperazone. Am J Surg 1982; 144:8-13.
28. Yellin AE, Heseltine PN, Berne TV, et al. The role of Pseudomonas species in patients treated with ampicillin and sulbactam for gangrenous and perforated appendicitis. Surg Gynecol Obstet 1985; 161:303-307.
29. Solomkin JS, Dellinger EP, Christou NV, Busuttil RW. Results of a multicenter trial comparing imipenem/cilastatin to tobramycin/clindamycin for intra-abdominal infections. Ann Surg 1990; 212:581-591.
30. Mosdell DM, Morris DM, Voltura A, et al. Antibiotic treatment for surgical peritonitis. Ann Surg 1991; 214:543-549.
31. Falagas ME, Barefoot L, Griffith J, Ruthazar R, Snydman DR. Risk factors leading to clinical failure in the treatment of intraabdominal or skin/soft tissue infections. Eur J Clin Microbiol Infect Dis 1996; 15:913-921.
32. Paterson DL, Rossi F, Baquero F, et al. In vitro susceptibilities of aerobic and facultative gram-negative bacilli isolated from patients with intra-abdominal infections worldwide: the 2003 Study for Monitoring Antimicrobial Resistance Trends (SMART). J Antimicrob Chemother 2005; 55:965-973.
33. Snydman DR, McDermott L, Cuchural GJ Jr, et al. Analysis of trends in antimicrobial resistance patterns among clinical isolates of Bacteroides fragilis group species from 1990 to 1994. Clin Infect Dis 1996; 23(Suppl 1):S54-S65.
34. Aldridge KE, Gelfand M, Reller LB, et al. A five-year multicenter study of the susceptibility of the Bacteroides fragilis group isolates to cephalosporins, cephamins, penicillins, clindamycin, and metronidazole in the United States. Diagn Microbiol Infect Dis 1994; 18:235-241.
35. Hackford A, Tally F, Reinhold R, et al. Prospective study comparing imipenem-cilastatin with clindamycin and gentamicin for the treatment of serious surgical infections. Arch Surg 1988; 123:322-326.
36. de Groot HG, Hustinx PA, Lampe AS, Oosterwijk WM. Comparison of imipenem/cilastatin with the combination of aztreonam and clindamycin in the treatment of intra-abdominal infections. J Antimicrob Chemother 1993; 32:491-500.
37. Tally FP, McGowan K, Kellum JM, et al. A randomized comparison of cefoxitin with or without amikacin and clindamycin plus amikacin in surgical sepsis. Ann Surg 1981; 193:318-323.
38. Drusano GL, Warren JW, Saah AJ, et al. A prospective randomized controlled trial of cefoxitin versus clindamycin-aminoglycoside in mixed anaerobic-aerobic infections. Surg Gynecol Obstet 1982; 154:715-720.
39. Collins MD, Dajani AS, Kim KS, et al. Comparison of ampicillin/sulbactam plus aminoglycoside vs. ampicillin plus clindamycin plus aminoglycoside in the treatment of intraabdominal infections in children. Pediatr Infect Dis J 1998; 17(Suppl 3):S15-S18.
40. Sirinek KR, Levine BA. A randomized trial of ticarcillin and clavulanate versus gentamicin and clindamycin in patients with complicated appendicitis. Surg Gynecol Obstet 1991; 172:30-35.
41. Brismar B, Malmborg A, Tunevall G, et al. Piperacillin-tazobactam versus imipenem-cilastatin for treatment of intra-abdominal infections. Antimicrob Agents Chemother 1992; 36:2766-2773.
42. Polk H, Fink M, Laverdiere M, et al. Prospective randomized study of piperacillin/tazobactam therapy of surgically treated intra-abdominal infection. Am Surg 1993; 59:598-605.
43. Vestweber K, Grundel E. Efficacy and safety of piperacillin-tazobactam in intra-abdominal infections. Eur J Surg 1994; 573(Suppl):57-60.
44. Niinikoski J, Havia T, Alhava E, et al. Piperacillin-tazobactam versus imipenem-cilastatin for treatment of intra-abdominal infections. Surg Gynecol Obstet 1993; 176:255-261.
45. Condon R, Walker A, Sirinek K, et al. Meropenem versus tobramycin plus clindamycin for treatment of intra-abdominal infections: results of a prospective, randomized, double-blind clinical trial. Clin Infect Dis 1995; 21:544-550.
46. Wilson S. Results of a randomized multicenter trial of meropenem versus clindamycin/tobramycin for the treatment of intra-abdominal infections. Clin Infect Dis 1997; 24(Suppl 2):S197-S206.
47. Brismar B, Malmborg AS, Tunevall G, et al. Meropenem versus imipenem/cilastatin in the treatment of intra-abdominal infections. J Antimicrob Chemother 1995; 35:139-148.
48. Solomkin JS, Yellin AE, Rotstein OD, et al. Ertapenem versus piperacillin/tazobactam in the treatment of complicated intraabdominal infections: results of a double-blind, randomized comparative phase III trial. Ann Surg 2003; 237:235-245.
49. Babinchak T, Ellis-Grosse E, Dartois N, Rose GM, Loh E, for the Tigecycline 301 and 306 Study Groups. The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial data. Clin Infect Dis 2005; 41(Suppl 5):S354-S367.
50. Petersen PJ, Jacobus NV, Weiss WJ, Sum PE, Testa RT. In vitro and in vivo antibacterial activities of a novel glycylcycline, the 9-t-butylglycylamido derivative of minocycline (GAR-936). Antimicrob Agents Chemother 1999; 43:738-744.
51. Gales AC, Jones RN. Antimicrobial activity and spectrum of the new glycylcycline, GAR-936, tested against 1,203 recent clinical bacterial isolates. Diagn Microbiol Infect Dis 2000; 36:19-36.
52. Petersen PJ, Bradford PA, Weiss WJ, Murphy TM, Sum PE, Projan SJ. In vitro and in vivo activities of tigecycline (GAR-936), daptomycin, and comparative antimicrobial agents against glycopeptideintermediate Staphylococcus aureus and other resistant gram-positive pathogens. Antimicrob Agents Chemother 2002; 46:2595-2601.
53. Milatovic D, Schmitz FJ, Verhoef J, Fluit AC. Activities of the glycylcycline tigecycline (GAR-936) against 1,924 recent European clinical bacterial isolates. Antimicrob Agents Chemother 2003; 47:400-404.
54. Sader HS, Jones RN, Dowzicky MJ, Fritsche TR. Antimicrobial activity of tigecycline tested against nosocomial bacterial pathogens from patients hospitalized in the intensive care unit. Diagn Microbiol Infect Dis 2005; 52:203-208.
55. Biedenbach DJ, Beach ML, Jones RN. In vitro antimicrobial activity of GAR-936 tested against antibiotic-resistant gram-positive blood stream infection isolates and strains producing extended-spectrum beta-lactamases. Diagn Microbiol Infect Dis 2001; 40:173-177.
56. Red Book: Pharmacy's Fundamental Reference (Drug Topics Red Book), 2006 Edition. Montvale, NJ: Thomson PDR; May 2006.
57. Brown SD, Traczewski MM. Comparative in vitro antimicrobial activity of a new carbapenem, doripenem: tentative disc diffusion criteria and quality control. J Antimicrob Chemother 2005; 55:944-949.
58. Johnson & Johnson Pharmaceutical Research & Development; Peninsula Pharmaceuticals. Doripenem in the treatment of complicated intra-abdominal infections. In: ClinicalTrials.gov [Internet]. Bethesda, MD: National Library of Medicine. Available at: www.clinicaltrials.gov/ct/show/NCT00210938. NLM identifier: NCT00210938. Accessed April 16, 2007.
59. Leaper D. Nosocomial infection. Br J Surg 2004; 91:526-527.